Emory Diabetes Education Training Academy
Avatar

Evolution of SGLT2-Inhibitors and GLP1-RA's Relating to Macrovascular Outcomes

By Emory Diabetes Education Training Academy FEATURING Francisco Pasquel
By Emory Diabetes Education Training Academy FEATURING Francisco Pasquel
106 views
April 26, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Related Content

AUTOPLAY
47:11
Houston Methodist Hospital

The Protein Myth: Our Obsession With Protein and How It Is Killing US

Feat. G. Davis
64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi
49:21
Physicians Committee for Responsible Medicine

Health of Vegetarians and Vegans: Findings From EPIC-Oxford and Othe…

Feat. T. J. Key
11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
23:35
Practical Ways to Achieve Targets in Diabetes Care

Is There a Future for HbA1c? (Moving Towards CGM: GMI and TIR)

Feat. I. Hirsch
18:43
ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo
15:06
Robert Busch

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

26:01
Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Feat. R. DeFronzo
37:21
University of Colorado Department of Medicine

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

Feat. R. Johnson
12:26
Juan Frias

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

15:33
Ken Fujioka

Could GLP-1's be a 'Game Changer' For Weight Loss? Ca…

17:44
Rita Jermyn

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

27:24
Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan
26:32
Practical Ways to Achieve Targets in Diabetes Care

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Feat. S. Nissen
20:24
Diana Isaacs

Tirzepatide for Type 2 Diabetes

26:49
Diana Isaacs

Tirzepatide Updates

44:43
Jason Fung

Type 2 Diabetes Aetiology and Reversibility

05:08
Susan Brian

The Differences Between the Products of GLP1's and GLP/GIPs

23:21
Practical Ways to Achieve Targets in Diabetes Care

TIR vs. A1c: Q&A/ Panel Discussion

Feat. J. Skyler, G. Aleppo, T. Danne, L. Barbour